Sartorius Stedim Biotech (CHIX:DIMP) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
82 GF Score
Price €187.40
GF Value €208.35
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Net Loan?

Net Loan only applies to banks and insurance companies.

CHIX:DIMP
82GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €187.40 is trading 10.1% below its estimated GF Value™ of €208.35. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for CHIX:DIMP:

  • Net Loan:
  • GF Value™: €208.35 vs. price of €187.40 (10.1% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score

Get the complete analysis for CHIX:DIMP

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€187.40
Price
€208.35
GF Value